– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Beloved in Finland, Helene Schjerfbeck is just becoming hot in Manhattan, where a show of paintings at the Met Museum is likely to leave you awe-struck. By Deborah Solomon As church bells chime and ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 ...

A video showcasing different elements of RIT's College of Art and Design, including glass blowing, fine arts, virtual productions, and more. Unleash your creativity — realize your vision. The College ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications. After buying Dren Bio’s B cell depletion ...

Dren Bio, a privately held, clinical-stage biotechnology company, has entered a strategic collaboration with Sanofi for the discovery and development of a next-generation B-cell depleting therapy to ...

Dren Bio, a privately held, US clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with ...